C-reactive protein is independently associated with fasting insulin in nondiabetic women

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 23, Issue 4, 2003, Pages 650-655

  Pradhan, Aruna D ^a   Cook, Nancy R ^a   Buring, Julie E ^a,b   Manson, JoAnn E ^a   Ridker, Paul M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

C reactive protein; Fasting insulin; Women

Indexed keywords

C REACTIVE PROTEIN; INSULIN; INTERLEUKIN 6;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; DIET RESTRICTION; FEMALE; HORMONE SUBSTITUTION; HUMAN; HUMAN EXPERIMENT; HYPERINSULINEMIA; INFLAMMATION; INSULIN RESISTANCE; LEAN BODY WEIGHT; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RISK FACTOR; THROMBOSIS;

ADIPOSE TISSUE; ADULT; ALCOHOL DRINKING; BIOLOGICAL MARKERS; BODY MASS INDEX; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HORMONE REPLACEMENT THERAPY; HUMANS; HYPERINSULINISM; INFLAMMATION; INSULIN; INSULIN RESISTANCE; INTERLEUKIN-6; MENOPAUSE; MIDDLE AGED; OBESITY; PREDICTIVE VALUE OF TESTS; RANDOMIZED CONTROLLED TRIALS; SMOKING;

EID: 0037390794     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000065636.15310.9C     Document Type: Article

References (31)

1. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327-334.
2. Barzilay JI, Abraham L, Heckbert SR, Cushman M, Kuller LH, Resnick HE, Tracy RP. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes. 2001;50:2384-2389.
3. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes. 2002;51:1131-1137.
4. Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GD, O'Reilly DS, Packard CJ, Sattar N. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes. 2002;51:1596-600.
5. Thorand B, Lowel H, Schneider A, Kolb H, Meisinger C, Frohlich M, Koenig W, C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg Cohort Study, 1984-1998. Arch Intern Med. 2003;163:93-99.
6. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study: Multiple Risk Factor Intervention Trial. Am J Epidemiol. 1996;144:537-547.
7. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
8. Tracy RP, Lemaitre RN, Psaty BM, Ives DG, Evans RW, Cushman M, Meilahn EN, Kuller LH. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol. 1997;17:1121-1127.
9. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843.
10. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Gallimore JR, Pepys MB. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ. 2000;321:199-204.
11. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-α, in vivo. J Clin Endocrinol Metab. 1997;82:4196-4200.
12. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab. 1998;83:847-850.
13. Despres JP. Abdominal obesity as important component of insulin-resistance syndrome. Nutrition. 1993;9:452-459.
14. Laakso M. How good a marker is insulin level for insulin resistance? Am J Epidemiol. 1993;137:959-965.
15. Howard G, Bergman R, Wagenknecht LE, Haffner SM, Savage PJ, Saad MF, Laws A, D'Agostino RB Jr. Ability of alternative indices of insulin sensitivity to predict Cardiovascular risk: Comparison with the 'minimal model': Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Ann Epidemiol. 1998;8:358-369.
16. Buring J, Hennekens C. The Women's Health Study: summary of the study design. J Myocard Ischemia. 1992;4:27-29.
17. Chevenne D, Trivin F, Porquet D. Insulin assays and reference values. Diabetes Metab. 1999;25:459-476.
18. Ridker P, Buring J, Cook N, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events. Circulation. 2003;107:391-397.
19. Kuczmarski RJ, Carroll MD, Flegal KM, Troiano RP. Varying body mass index cutoff points to describe overweight prevalence among U. S. adults: NHANES III (1988 to 1994). Obes Res. 1997;5:542-548.
20. Gallois Y, Vol S, Caces E, Balkan B. Distribution of fasting serum insulin measured by enzyme immunoassay in an unselected population of 4.032 individuals: reference values according to age and sex. D. E. S. I. R. Study Group Donnees Epidemiologiques sur le Syndrome d'Insulino-Resistance. Diabetes Metab. 1996;22:427-431.
21. Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia. 1998;41:1241-1248.
22. Hotamisligil GS, Amer P, Caro JF, Atkinson RL. Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J Clin Invest. 1995;95:2409-2415.
23. Carey VJ, Walters EE, Colditz GA, Solomon CG, Willett WC, Rosner BA, Speizer FE, Manson JE. Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women: the Nurses' Health Study. Am J Epidemiol. 1997;145:614-619.
24. Ruige JB, Assendelft WJ, Dekker JM, Kostense PJ, Heine RJ, Bouter LM. Insulin and risk of cardiovascular disease: a meta-analysis. Circulation. 1998;97:996-1001.
25. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: Associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol. 1999;19:972-978.
26. Hak AE, Stehouwer CD, Bots ML, Polderman KH, Schalkwijk CG, Westendorp IC, Hofman A, Witteman JC. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol. 1999;19:1986-1991.
27. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102:42-47.
28. Fernandez-Real JM, Vayreda M, Richart C, Gutierrez C, Broch M, Vendrell J, Ricart W. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab. 2001;86:1154-1159.
29. Hak AE, Pols HA, Stehouwer CD, Meijer J, Kiliaan AJ, Hofman A, Breteler MM, Witteman JC. Markers of inflammation and cellular adhesion molecules in relation to insulin resistance in nondiabetic elderly: the Rotterdam study. J Clin Endocrinol Metab. 2001;86:4398-4405.
30. Harris MI. Impaired glucose tolerance in the U. S. population. Diabetes Care. 1989;12:464-474.
31. Nijpels G. Determinants for the progression from impaired glucose tolerance to non-insulin-dependent diabetes mellitus. Eur J Clin Invest. 1998;28(suppl 2):8-13.